Canada, Sirius Genomics Receives Grant to Develop a Sepsis Companion Diagnostic

Sirius Genomics, a Vancouver, Canada-based drug-enabling company that develops pharmacogenomic (PGx) diagnostics that lead to better patient outcomes through personalized medicine, has received a grant from the National Research Council of Canada – Industrial Research Assistance Program (NRC-IRAP).
The funds from the grant will be used to study genomic correlations in severe sepsis patients and to continue development of Sirius’ pharmacogenomic diagnostic intended to assess responsiveness to recombinant human activated Protein C in patients with severe sepsis at high risk of death.
The NRC-IRAP provides both technical and business-oriented advisory services along with potential financial support to qualified innovative Canadian small- and medium-sized enterprises. The financial assistance for granted by the Government of Canada’s Economic Action Plan.

Join the discussion